Siemens Healthcare announced FDA approval of their MAGNETOM Prisma, a 3T MRI scanner.
Siemens Healthcare announced FDA approval of their MAGNETOM Prisma, a 3T MRI scanner designed to provide high spatial and temporal resolution, particularly in highly demanding applications.
The MAGNETOM Prisma features XR Gradients, which combine 80 milliTesla per meter with a 200T-per-meter-per-second slew rate to offer a configuration unavailable in any other commercial whole-body system. The system is designed to maintain precision throughout long, demanding applications such as functional MRI. The system’s first-to-market Diffusion Spectrum Imaging (DSI) acquisition enables the user to potentially resolve fine anatomical details of the brain such as crossing white-matter fibers, the company said.
MAGNETOM Prisma’s benchmark homogeneity and advanced shimming solutions allow for finer, more effective compensation of patient-induced field disturbances. The MAGNETOM Prisma has Siemens’ Dot (Day optimizing throughput) engines that enable consistency for research applications and clinical work, the company said. The Dot engine brings automation and reproducibility to investigations across subjects, time points, and institutions.
Siemens will offer onsite upgrades to the MAGNETOM Prisma to customers who have already installed the MAGNETOM Trio.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
Breast MRI and Dense Breasts: A Closer Look at Early Findings from a New Prospective Trial
May 2nd 2024Supplemental breast MRI had a cancer detection rate (CDR) of 20/1000 and a positive predictive value (PPV) of 50 percent, according to preliminary findings from a prospective trial involving women with heterogeneously or very dense breasts.